2160 logo

MicroPort CardioFlow Medtech Corporation Stock Price

SEHK:2160 Community·HK$1.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

2160 Share Price Performance

HK$0
-4.70 (-100.00%)
HK$0
-4.70 (-100.00%)
Price HK$0

2160 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks
0 Rewards

MicroPort CardioFlow Medtech Corporation Key Details

US$57.0m

Revenue

US$20.0m

Cost of Revenue

US$37.1m

Gross Profit

US$55.9m

Other Expenses

-US$18.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.015
64.97%
-32.99%
80.5%
View Full Analysis

About 2160

Founded
2009
Employees
1415
CEO
Ruinian Zhang
WebsiteView website
www.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.

Recent 2160 News & Updates

Recent updates

No updates